New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know
AbstractSkin cancer is one of the most common neoplasms worldwide, with a surprising tendency to increase its incidence. As with many cancer types nowadays, early diagnosis and proper management carries an excellent prognosis, up to 5-year survival rate of above 95% for most skin cancers, even though the long-term survival rate among metastatic melanoma patients remains only 5%. This review aims to summarize recent discoveries in epigenetic changes connected with cutaneous malignant melanoma (CMM), comprising of DNA methylation, histone modifications, miRNA regulation, nucleosome positioning and chromatin remodelling. Undoubtedly, personalised medicine based on both genetic and epigenetic changes of cancer is the future, the question remains: how long will it take to transport this treatment from the bench to the bedside? View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nguyen, M.; Dobosz, P. New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know. Epigenomes 2017, 1, 3.
Nguyen M, Dobosz P. New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know. Epigenomes. 2017; 1(1):3.Chicago/Turabian Style
Nguyen, Marzena; Dobosz, Paula. 2017. "New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know." Epigenomes 1, no. 1: 3.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.